Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2009

View Archived Issues

AlphaRx and Venturepharm sign agreement for drug development center in China

Laboratory Corporation acquires Monogram Biosciences pursuant to cash tender offer

New inhibitors of the MDM2-p53 interaction reported by Roche as oncolytics

Anesiva and Arcion Therapeutics sign definitive merger agreement

FDA requests stronger cancer warnings in prescribing information for TNF blockers

Radius reports results from phase II clinical trial of BA-058 in osteoporosis

Rib-X reports results from phase II clinical trial of radezolid in CAP

European Commission approves Novartis' Afinitor for RCC patients

Acura submits briefing package to FDA for Acurox NDA in moderate to severe pain

MJFF grants funding to Ceregene for long-term testing in phase II trial of CERE-120

ARRY-520 shows similar preclinical activity to paclitaxel without NF-kappaB and cytokine activation

Phase I/II data support clinical activity of icotinib in later stage non-small cell lung cancer

Neurological recovery induced by fenofibrate/simvastatin in rat model of traumatic brain injury

Rosiglitazone prevents stroke-induced inflammation in mouse model of type 2 diabetes

Early phase I/II data suggest safety and immunogenicity of HIV DNA vaccine in healthy subjects

Soluble epoxide hydrolase inhibitors described by Arete Therapeutics for vascular conditions

French researchers claim novel anticancer compounds

Amgen presents PI3Kalpha inhibitors for cancer treatment

Dipeptidyl peptidase IV inhibitors in early development at LG Life Sciences

Genelabs and Novartis disclose novel compounds for treating hepatitis C viral infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...